ADA. Microvascular complications and foot care. Sec. 9. In standards of medical care in diabetes - 2015. Diabetes Care. 2015;38:S58–66.
Google Scholar
KDOQI (Kidney Disease Outcomes Quality Initiative). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12–154.
ADA. Glycemic targets. Sec. 6. In standards of medical care in diabetes - 2015. Diabetes Care. 2015;38:S33–40.
Google Scholar
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–36.
PubMed Google Scholar
KDOQI (Kidney Disease Outcomes Quality Initiative). Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012, 60:850–886.
DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.
Google Scholar
DCCT. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703–20.
Google Scholar
EDIC. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.
Google Scholar
Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000;23:1478–85.
Article CAS PubMed Google Scholar
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
CAS PubMed Google Scholar
UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.
Google Scholar
Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172:761–9.
PubMed Central PubMed Google Scholar
Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
CAS PubMed Google Scholar
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
CAS PubMed Google Scholar
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
CAS PubMed Google Scholar
Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int. 2015;87(1):20-30. doi: 10.1038/ki.2014.128. Epub 2014 Apr 30.
Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7.
PubMed Google Scholar
Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708–15.
Article PubMed Central CAS PubMed Google Scholar
Ramirez SP, McCullough KP, Thumma JR, Nelson RG, Morgenstern H, Gillespie BW, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care. 2012;35:2527–32.
Article PubMed Central CAS PubMed Google Scholar
Adler A, Casula A, Steenkamp R, Fogarty D, Wilkie M, Tomlinson L, et al. Association between glycemia and mortality in diabetic individuals on renal replacement therapy in the U.K. Diabetes Care. 2014;37:1304–11.
Article CAS PubMed Google Scholar
Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int. 2010;30:72–9.
CAS PubMed Google Scholar
Kalantar-Zadeh K. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint. Diabetes Care. 2012;35:1625–8.
Article PubMed Central PubMed Google Scholar
Freedman BI. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care. 2012;35:1621–4.
Article PubMed Central PubMed Google Scholar
Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984;27:351–7.
Article CAS PubMed Google Scholar
Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4.
Article PubMed Central CAS PubMed Google Scholar
Epocrates Online. https://online.epocrates.com.
de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34:2496–501.
Article PubMed Central PubMed Google Scholar
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
Article PubMed Central CAS PubMed Google Scholar
Wile DJ, Toth C. Association of Metformin, Elevated Homocysteine, and Methylmalonic Acid Levels and Clinically Worsened Diabetic Peripheral Neuropathy. Diabetes Care. 2010;33:156–61.
Article PubMed Central CAS PubMed Google Scholar
Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094–102.
CAS PubMed Google Scholar
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;14(4):CD002967.
Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18:779–84.
Article CAS PubMed Google Scholar
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.
Article PubMed Central PubMed Google Scholar
Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008;40:411–7.
CAS PubMed Google Scholar
Eppenga WL, Lalmohamed A, Geerts AF, Derijks HJ, Wensing M, Egberts A, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care. 2014;37:2218–24.
Article CAS PubMed Google Scholar
Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37:2291–5.
Article CAS PubMed Google Scholar
Holstein A, Plaschke A, Hammer C, Ptak M, Kuhn J, Kratzsch C, et al. Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. Eur J Clin Pharmacol. 2003;59:747–54.
CAS PubMed Google Scholar
Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol. 2009;5:225–41.
CAS PubMed Google Scholar
Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia. 1973:331–8.
Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. Diabetes Care. 2013;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17.
Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes. 2004;53 Suppl 3:S151–5.
Article CAS PubMed Google Scholar
Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60:90–5.
CAS PubMed Google Scholar
Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886–91.
Article CAS PubMed Google Scholar
Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabetic Med. 2015;32(3):305-13. doi: 10.1111/dme.12627. Epub 2014 Dec 3.
Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7.
Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–70.
PubMed Google Scholar
Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–4.
Article CAS PubMed Google Scholar
Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939–46.
CAS PubMed Google Scholar
Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014;5:355–66.
PubMed Central CAS PubMed Google Scholar
Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317–27.
PubMed Central CAS PubMed Google Scholar
Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol. 2008;66(4):568-9. doi: 10.1111/j.1365-2125.2008.03221.x. Epub 2008 May 15.
US Food and Drug Administration. Information for Healthcare Professionals: Reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta). 2009.
Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract. 2011;17:345–55.
PubMed Google Scholar
Albiglutide Full Prescribing Information. 2014. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF.
Dulaglutide Full Prescribing Information. 2015. http://pi.lilly.com/us/trulicity-uspi.pdf.
Chang YT, Wu JL, Hsu CC, Wang JD, Sung JM. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998–2009. Diabetes Care. 2014;37:277–85.
Article PubMed Google Scholar
ADA. Cardiovascular disease and risk management. Sec. 8. In standards of medical care in diabetes - 2015. Diabetes Care. 2015;38:S49–57.
Google Scholar
Page 2
Medication class
CKD stages 3 and 4 and predialysis stage 5
Insulin
Glargine
No advised dose adjustment*
Detemir
No advised dose adjustment*
NPH
No advised dose adjustment*
Regular
No advised dose adjustment*
Aspart
No advised dose adjustment*
Lispro
No advised dose adjustment*
Glulisine
No advised dose adjustment*
First-generation sulfonylureas
Acetohexamide**
Avoid use
Chlorpropamide
eGFR 50–80: reduce dose by 50 %
eGFR <50: avoid use
Tolazamide
Avoid use
Tolbutamide
Avoid use
Second-generation sulfonylureas
Glipizide
eGFR <30: use with caution
Glimepiride
eGFR <60: use with caution
eGFR <30: avoid use
Glyburide
Avoid use
Gliclazide**
No dose adjustment
Glinides
Repaglinide
No dose adjustment but may wish to use caution with eGFR <30
Nateglinide
eGFR <60: avoid use (but may consider use if patient is on hemodialysis)
Biguanides
Metformin***
Per FDA, do not use if serum Cr ≥ 1.5 mg/dL in men ≥ 1.4 mg/dL in women.
Consider
eGFR ≥45-59: use caution with dose and follow renal function closely (every 3–6 months)
eGFR ≥30-44: max dose 1000 mg/day or use 50 % dose reduction. Follow renal function every 3 months. Do not start as new therapy.
eGFR <30: avoid use
Thiazolidinediones
Pioglitazone
No dose adjustment
Rosiglitazone
No dose adjustment
Alpha-glucosidase inhibitors
Acarbose
serum Cr >2 mg/dl: avoid use
Miglitol
eGFR <25 or serum Cr >2 mg/dl: avoid use
DPP-4 inhibitor
Sitagliptin
eGFR ≥50: 100 mg daily
eGFR 30–49: 50 mg daily
eGFR < 30: 25 mg daily
Saxagliptin
eGFR > 50: 2.5 or 5 mg daily
GFR ≤ 50: 2.5 mg daily
Linagliptin
No dose adjustment
Alogliptin
eGFR >60: 25 mg daily
eGFR 30–59: 12.5 mg daily
eGFR <30: 6.25 mg daily
SGLT2 inhibitors
Canagliflozin
eGFR 45 to < 60: max dose 100 mg once daily
eGFR <45, avoid use
Dapagliflozin
eGFR < 60, avoid use
Empagliflozin
eGFR < 45, avoid use
Dopamine receptor agonist
bromocriptine mesylate
No dose adjustment known but not studied: use with caution
Bile acid sequestrant
Colesevelam
No dose adjustment known but limited data
GLP-1 Agonists
Exenatide
eGFR 30–50: use caution
eGFR <30: avoid use
Liraglutide
No dose adjustment but use caution when starting or titrating the dose